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Background
An easy and stable venous access is essential in hemophilic children who receive regular
prophylaxis or immune tolerance induction treatment. Central venous access devices
improve treatment feasibility, but their use is complicated by infection and/or thrombosis.
Arteriovenous fistula (AVF) has been evaluated as an alternative to central venous access
devices in hemophilic children since 1999.
Design and Methods
This study provides results obtained in a large series after seven years of follow-up. 
Results
From 1999 to 2008, 43 procedures were performed in 38 children (median age: 2.7 years).
Thirty-five AVFs (81%) achieved maturation after a median of 58 days and were used for
a median of five years (range: 0.4-8.5). A brachial artery caliber larger than 1.2 mm was
associated with successful maturation (p<0.05). Complications with some impact on arte-
riovenous fistula use or duration were observed in 14/43 procedures (32%) and in 13/38
children (34%). Age at arteriovenous fistula creation was younger in children who lost
arteriovenous fistula patency (p<0.05) and aneurysms were more frequent in children who
were on daily treatment regimen and thus had a greater cumulative number of arteriove-
nous fistula accesses (p<0.05). At the end of the follow-up period, 22 AVFs were still in use
and 9 had been surgically dismantled. Arteriovenous fistula use allowed long-term pro-
phylaxis (up to 8.5 years) in 11 children and the completion of immune tolerance induc-
tion without interruptions in 18 children. 
Conclusions
This study confirms the feasibility of arteriovenous fistula with an acceptable rate of com-
plications and suggests that its use is particularly favorable in children with inhibitors in
whom it should be considered as first-choice venous access.
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Introduction
Children with hemophilia need an easy and stable
venous access to receive factor concentrates on a regular
basis for primary prophylaxis or immune tolerance
induction (ITI) regimens. Even though peripheral veins
are the first choice, central venous access devices
(CVADs) are often necessary to improve treatment fea-
sibility,1 but their use is complicated by infections and/or
thrombosis.2 Arteriovenous fistula (AVF) is the preferred
access for children on hemodialysis, because it is a long-
lasting autologous access that carries a very low risk of
infections.3-6 Since 1999, AVF has been evaluated as a
suitable alternative to CVADs in hemophilic children.
Our preliminary experience7 showed that AVF was well
accepted by children and parents because it is easy to
use in the home setting, does not limit the child’s activi-
ties and is associated with a low rate of complications.7
However, a prolonged follow-up was warranted to
establish the safety of this approach. This study pro-
vides data on the long-term use of AVF in hemophilic
children and evaluates the impact of this mode of
venous access on the feasibility of treatment in children
with or without factor VIII inhibitors.
Design and Methods
All children included in the study were prospectively
followed-up from fistula creation and data collection
was approved by the Institutional Review Board of the
Angelo Bianchi Bonomi Hemophilia and Thrombosis
Center of Milan. The need and types of venous accesses
were evaluated in the unselected cohort of children with
severe or moderately severe hemophilia, aged < 12 years
(the age of the eldest patient who underwent AVF cre-
ation) regularly followed-up in Milan (Figure 1), while
complications related to AVF creation and long-term
outcome were also analyzed including procedures per-
formed in children referred from other Italian centers. 
Patients
Children who needed an artificial venous access to
allow home treatment because they lacked suitable
peripheral veins were included. Concomitant cardiac or
vascular diseases represented exclusion criteria. Risks
and benefits associated with the use of AVFs and CVADs
were discussed with parents or guardians and a written
informed consent for the surgical procedure was
obtained.
Perioperative treatment 
To create AVF, patients with hemophilia A or B with-
out inhibitors were treated with factor VIII or IX (FVIII
or FIX) concentrates for 5-6 days.7 Patients with high-
responding inhibitors were treated with recombinant
activated FVII (rFVIIa), administered by bolus injection
or by continuous infusion (CI) for 5-6 days.7
Arteriovenous fistula creation 
Surgical eligibility was evaluated by the same vascular
surgeon (LB) and the most suitable vascular site and the
configuration of AVF were decided according to age,
vessel size and blood flow,7 the non-dominant upper
limb being preferred if possible. Caregivers were recom-
mended not to access the chosen vessels until AVF cre-
ation. 
AVFs were created under general anesthesia. Broad-
spectrum intravenous antibiotic prophylaxis was given
30 min before surgery. AVFs were created proximally in
the forearm at the elbow crease by an anastomosis
between the brachial artery and a nearby vein by end-to-
side or side-to-side techniques.8,9 Peripheral pulses were
checked by palpation and Doppler ultrasound (US)
examination performed after the procedure was com-
pleted. Sutures were removed after 15-20 days.
Follow-up evaluation
The flow through AVF was evaluated by physical and
Doppler US examination prior to discharge, at suture
removal and monthly until AVF maturation. Successful
maturation was defined as arterialization and dilatation
of the vein adequate to allow factor concentrate infu-
sion. Caregivers were trained to access AVF by conven-
tional venepuncture technique at the Hemophilia Center
and continued the prescribed treatment regimen at
home. Afterwards, patients were clinically evaluated as
outpatients at least every three months in order to
undergo comparative physical examination of the upper
limbs. Doppler US and echocardiography were carried
out at least once a year. Caregivers were advised to
report promptly any sign or symptom referable to the
creation of the AVF. AVFs were dismantled as soon as
peripheral veins became suitable for regular access.
Figure 1. Prescribed treatment regimens, need for artificial
venous access and types of venous accesses in the cohort of chil-
dren regularly followed-up at the Hemophilia Center of Milan
between 1987 and 2008. (PUPs denotes previously untreated
patients; AVF: arteriovenous fistula; ITI: immune tolerance induc-
tion; CVAD: central venous access device). 
107 children
6 PUPs
65 (64%)
without inhibitors
36 (36%)
with inhibitors
31 (86%)
on ITI
27 (75%) 20 (41%) 
14 (70%)
CVADs
12 (44%)
CVADs
5 AVFs (42%)
after removal
3 AVFs (21%)
after removal
6 (30%)
AVFs
15 (56%)
AVFs
9/20 (45%) 20/27 (74%) 
Need for venous access
Types of venous access
Total number of
children who
underwent AVF
creation
101 children
49 (75%) 
on prophylaxis
©F
er
r
ta
 S
to
rti
 F
un
da
tio
n
Statistical analysis
Continuous variables, expressed as median values
and ranges, were compared by the Student t-test or the
Mann-Whitney U-test. Categorical variables, expressed
as frequencies and percentage values, were compared
by χ2 or Fisher’s exact test. Correlation coefficients were
calculated by Pearson’s or Spearman’s rho test. The
association between complications and age at AVF cre-
ation, AVF configuration, brachial artery caliber,
inhibitor status, cumulative number of AVF accesses,
number of accesses per month and daily treatment reg-
imen was evaluated. The small number of complicated
cases did not allow a multivariate analysis to be per-
formed. The duration of AVF use was calculated from
the first access onwards, if not otherwise specified. All
reported p values are two-sided and values <0.05 were
considered significant. All analyses were performed by
using SPSS software (release 16.0, SPSS Inc.).
Results
Patients’ characteristics
Between January 1987 and June 2008, an unselected
cohort of 107 hemophilic children with severe or mod-
erately severe hemophilia (106 boys with FVIII/IX ≤2
IU/dL and one girl with factor VII <1 IU/dL) aged ≤12
years was regularly followed-up at the Hemophilia
Center. The prescribed treatment regimens, the need for
a venous access and the types of venous accesses pro-
vided to these children are shown in Figure 1. Since the
‘90s the use of CVADs in hemophiliac children has been
implemented at our Center,10 however due to the high
rate of infectious complications, AVF was evaluated as a
candidate option.7 The first AVFs were created from
1999 in children who had their CVADs removed
because of infection; the use of AVF was then gradually
introduced as the first option in patients who needed a
long-lasting venous access. For this reason CVADs were
mainly used at our center until 1999 (only 5 implanted
after 2000) and AVFs were preferred afterwards. 
Nine additional children (6 hemophiliacs with
inhibitors, 2 without and one factor X deficient boy)
were referred to us for AVF creation from other Italian
Centers, so that in all 38 children underwent AVF cre-
ation between 1999 and 2008. Patients’ characteristics
are shown in Table 1.
Surgical procedure and perioperative hemostatic
treatment
Over eight years, 43 internal AVFs were created in 38
children because 5 underwent a second procedure at the
opposite limb after a median of seven months (range: 4-
7). The type of anastomosis was radio-cephalic in one
(2%), brachio-cephalic in 7 (17%), brachio-basilic in 4
(9%), brachio-median-cephalic in 4 (9%) and brachio-
median-basilic in 27 (63%). The median caliber of the
brachial artery prior to AVF creation was 1.2 mm (range
0.8-2.1). 
The perioperative hemostatic treatment is shown in
Table 2. Children without inhibitors were treated with
recombinant FVIII or FIX products (rFVIII/FIX) for 5-6
days. The factor X deficient boy and the factor VII defi-
cient girl (who underwent AVF creation twice) received
a prothrombin complex concentrate and plasma-
derived factor VII concentrate.7 Children with inhibitors
were treated with rFVIIa when inhibitor titer exceeded
10 BU/mL (Table 2). rFVIIa was administered every 2-3
h for 24-48 h, every four hours till post-operative day 4
and every six hours for an additional 48 hours when
given by bolus. Of the 4 children treated with high-dose
rFVIII, 2 received CI (Table 2) and 2 received twice daily
infusions for 5-6 days. Of these children, 2 continued to
receive FVIII according to ITI regimens through a CVAD
until AVF maturation, one with a persistent low-titer
inhibitor started ITI after AVF maturation and one
underwent regular prophylaxis because the inhibitor
was transient (see below).
Follow-up and complications
The median follow-up from AVF creation was 7.0
years (range: 3.0-8.8). Of 43 AVFs created, 35 (81%)
Arteriovenous fistula in children with hemophilia
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Table 1. Characteristics of the 38 children with arteriovenous fistula.
Gender (M/F) 37/1
Median age at AVF creation, years (range) 2.7 (0.9-11.9)
Median weight at AVF creation, kg (range) 14 (10-35)
Inherited coagulation factor deficiency
Factor VIII 34 (88%)
Factor IX 2 (6%)
Factor VII 1 (3%)
Factor X 1 (3%)
Deficient factor <1 IU/dL 37 (97%)
Previous CVAD insertion 11 (29%)a
Factor VIII inhibitors at the time of AVF creation 23 (60%)b
aSeven ports and 6 external CVADs in 11 children. bThree additional children developed
inhibitors after AVF creation and one of them underwent a second procedure after inhibitor
development.
Table 2. Perioperative hemostatic treatment provided to 36 hemophilic chil-
dren for 40 procedures.1
Children without Children with Children with
inhibitors2 inhibitors inhibitors
(n=13)3 > 10 BU/mL2 < 10 BU/mL2
(n=20)3 (n=4)
Number of procedures 15 21 4
Median pre-operative 90 IU/kg 164 µg/kg 173 IU/kg
dose (range) (67-133) (109-240) (118-384)
Median daily dose 67 IU/kg 90-120 µg/kg 100 IU/kg/bid
(range) (57-71) (88-115)
Median post-infusion 88 IU/dL n.a. 128 IU/dL
FVIII/IX level (range) (53-185) (80-170)
Median trough FVIII/IX 28 IU/dL n.a. 38 IU/dL
level (range) (10-31) (27-57)
Number of cases − 10 2
treated with CI (dose) (20 µg/kg/h) (4-5 IU/kg/h)
1Data on the FVII deficient girl (2 procedures) and the FX deficient boy (one procedure) are
not reported in the table. 2Inhibitor status at the time of surgery. 3One child who underwent 2
procedures and developed inhibitors in between is counted twice.n.a.: not applicable.
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achieved maturation. Time to AVF maturation ranged
between 21 and 135 days (median: 58) and it was neither
correlated with age at AVF creation or brachial artery cal-
iber (r=-0.005 and r=-0.04, respectively; p=ns), nor asso-
ciated with AVF configuration. Mature AVFs were used
for a median of 5.0 years (range: 0.4-8.5). The number of
AVF accesses per patient/month ranged between 9 and
48 (median: 16), accounting for a cumulative number of
accesses per patient between 166 and 2,036 (median:
1052). Twenty-nine children (76%) used AVF according
to the initial indication (10 for prophylaxis and 19 for
ITI), while 6 did not, because 2 developed inhibitors
after surgery and underwent ITI, one had a transient
inhibitor and started prophylaxis, and 3 were non-com-
pliant to ITI regimens. The latter 3 children, referred
from other centers, ultimately used AVFs to be treated
on demand with by-passing agents for a median of 6.8
years (range: 4.2-7.5). The details of AVF use according
to prophylaxis or ITI regimens are shown in Table 3. 
Inadequate maturation of AVF was observed after
8/43 procedures (19%) in 7/38 children (18%), however
only 3 (8%) could not benefit from AVF use, because 5
underwent a second procedure that was successful in 4.
Among all the variables analyzed, the brachial artery cal-
iber was associated with the likelihood of AVF matura-
tion, being larger in patients who achieved AVF matura-
tion (median: 1.3 mm, range: 0.8-2.1 vs. 0.9 mm, range:
0.8-1.2 in children who did not achieve maturation;
p<0.01). No linear correlation was found between
brachial artery caliber and age at AVF creation (r=0.09;
p=ns).
Post-operative local hematoma occurred after 8 proce-
dures (19%) in 8 children (21%). Six had inhibitors and
received rFVIIa by CI (n=2) or repeated bolus (n=4).
Bleeding was controlled by adding rFVIIa bolus to CI or
switching rFVIIa administration from CI to repeated
bolus in the former, and by shortening the interval
between each bolus in the latter. The remaining 2
patients had no detectable inhibitors at surgery, but low-
titer inhibitors were detected post-operatively in both,
so that the hematomas were managed by increasing the
frequency of FVIII infusions as previously described.7
The presence of inhibitors was the only factor associat-
ed with post-operative bleeding (8/27, 30% vs. 0/16 in
non-inhibitor children; p<0.05).
Symptoms referable to distal steal syndrome included
coldness and tingling of the hand ipsilateral to AVF and
were reported in 4/35 children with mature AVF (11%).
Symptoms mainly occurred during winter and sponta-
neously recovered within the first year from AVF cre-
ation, never recurring afterwards. In these patients,
Doppler US examination showed a slight increase of the
flow rates through AVFs that did not require any reme-
dial intervention. No association was found between the
occurrence of distal steal syndrome and age at AVF cre-
ation, brachial artery caliber or AVF configuration.
Loss of patency was observed only in 4 of 35 children
with mature AVF after a median of 1.7 years (range: 0.4-
4.1), so that patency rate was 89% at five years. In a 2-
year old inhibitor child a symptomatic thrombosis of a
venous branch downstream the fistula occurred after
nine months of uncomplicated AVF use for ITI and on
demand rFVIIa treatment.7 Pain, swelling and warmness
of the hand recovered spontaneously within three
weeks and AVF was used for 24 additional months for
ITI. Overall, treatment was continued through collateral
veins in 3 patients, while a port-a-cath was implanted in
one. Age at AVF creation was significantly younger in
children who lost AVF patency (1.7 years, range: 1.3-2.1
vs. 2.7 years, range: 1.5-11.9 in children who maintained
patent AVF; p<0.01); no differences were found with
respect to other variables. 
Limb hypertrophy ipsilateral to AVF was observed in
a child at the age of 11 years after 5.4 years of thrice-
weekly AVF use for regular prophylaxis. AVF was at first
surgically remodeled to reduce the caliber of the anasto-
mosis (from 8.0 to 4.5 mm) in order to decrease the
blood flow, and then dismantled after 1.7 additional
years of use. Echocardiography showed a mild dilatation
of the left ventricle that completely recovered after AVF
remodeling. The upper limb ipsilateral to AVF remained
bigger than the opposite (length 74 vs. 73 cm; arm cir-
cumference 32 vs. 27.5 cm and forearm circumference 29
vs. 26 cm).
Aneurysmatic dilatation of the vein developed in 4
children (4/35, 11%) with inhibitors who used the AVF
daily, first for ITI and then for a prophylactic regimen for
a median of 4.6 years (range: 3-7.5) prior to aneurysm
formation. Two patients underwent surgical AVF dis-
mantlement, while one underwent surgical AVF remod-
eling after five years of use and subsequent dismantle-
ment after an additional 1.6 years. AVF dismantlement
and transition to peripheral veins is planned in the
remaining patient. Aneurysmatic dilatation was more
frequent in children on a daily treatment regimen (4/17,
24% vs. 0/18 in children not treated daily; p<0.05) who
underwent a greater cumulative number of AVF access-
es (median 1,594, range: 1,054-2,036 vs. 1,020, range:
166-1,965 in children without aneurysm; p<0.05), while
no statistically significant difference was found accord-
ing to the inhibitor status.
Overall, complications with some impact on AVF use
Table 3. Details on the use of mature AVFs in 32 children according to prophylaxis and ITI regimens.
Treatment Patients Median number of Median number of accesses Median duration
regimen accesses per patient per patient/month (range) of AVF use, years (range)
ITI1 21 1,192 20 5 
(166-2,036) (12-48) (0.4-8.5)
Prophylaxis 11 602 14 4 
(367-1,537) (9-16) (2-8.5)
1All patients who completed ITI continued treatment through AVF either on regular prophylaxis or on demand.Data are referred to the whole period of AVF use.
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or duration (i.e. excluding hematomas and distal steal
syndrome) occurred in 14/43 procedures (32%) in 13/38
patients (34%), including AVF overflow (AVF flow rate
up to 2,200 mL/min) without US signs of cardiac
involvement observed in one child after 6.9 years of
AVF use. In this case the AVF was dismantled and treat-
ment continued through peripheral veins. 
At the end of the follow-up period, 22 AVFs (51%)
were still in use, since 8 did not mature, 4 did not main-
tain blood flow and 9 were surgically dismantled.
Reasons for surgical dismantlement are summarized in
Table 4. All patients but one whose AVF lost patency or
was surgically dismantled were able to continue the
prescribed regimen through peripheral veins.
Treatment feasibility through arteriovenous fistula
AVF creation allowed long-term prophylaxis (FVIII:
25-40 IU/kg thrice or twice weekly; FIX: 40-50 IU/kg
twice weekly) in 11 children but one who lost patency
after 4.1 years required port placement. AVF is still in
use in 7 children (64%) on regular prophylaxis. ITI regi-
mens (ranging from 50 IU/kg thrice weekly to 200
IU/kg/day) were administered through AVF in 21/22
inhibitor children compliant to treatment (95%, one did
not achieve AVF maturation). Daily ITI regimens (100-
200 IU/kg once a day) were given to 18/21 patients
(86%); the median ITI duration was 15 months (range:
5-51). A second ITI course was administered through
AVF in 4 children who previously failed or relapsed
(median duration of the second course: 16 months,
range: 6-29). 
At the end of the follow-up period, at least one ITI
course was completed in 18/21 children (86%, ITI ongo-
ing in the remaining 3). All 13 children who achieved
tolerance (72%) continued to use AVF according to pro-
phylactic regimens (median duration of prophylaxis: 4.4
years, range: 0.9-6.8), except one who lost AVF patency
just after ITI completion and received prophylaxis
through the collateral veins close to the anastomosis.
Similarly, all 5 children who failed ITI continued to use
AVFs for treatment with by-passing agents according to
licensed dosages for a median of 2.2 years (range: 1.5-4).
Discussion
Modern treatment of children with severe hemophil-
ia is based on primary prophylaxis to prevent joint dam-
age11 and on ITI to eradicate inhibitors.12 Both treat-
ments are usually started at very young ages, so that
venous access often represents a major barrier to treat-
ment feasibility. CVADs have been widely used in this
setting but the high rate of infectious complications,
usually leading to early removal, has a negative impact
on treatment feasibility and outcome, particularly in
children with inhibitors who require prolonged and
intensive ITI regimens.10,13,14 The use of AVF as an alter-
native venous access was introduced at our center in 23
hemophilic children and was associated with an accept-
able rate of complications (35%) after a median follow-
up period of 2.6 years.7 In this study results are provid-
ed for larger series of children who were followed-up
for a median period of seven years after AVF creation. A
mature AVF was ultimately obtained in all but 3 chil-
dren (8%). High rates (up to 30%) of maturation failure
have been reported in hemodialysis patients,15,16 howev-
er in this setting several metabolic factors, as well as
female gender and radiocephalic configuration, were
identified as predictors of non-maturation.17 In our
cohort all but one child were males and all AVF were
created proximally by using the brachial rather than the
radial artery (with only one exception). A brachial artery
caliber smaller than 1.2 mm was associated with failure
of AVF maturation, however no correlation with age
was found, suggesting that successful AVF maturation
can also be achieved in young children. Moreover, an
age at AVF creation younger than 2.1 years was a pre-
dictor of patency loss. In hemodialysis patients, inten-
sive AVF use has been reported to affect patency;16 in
our experience symptomatic thrombosis indeed
occurred in one child who used AVF intensively for both
ITI and on demand treatment with rFVIIa. Frequent
injections of procoagulant agents may have favored the
development of local thrombosis in this patient.
Short-term complications such as post-operative
hematoma and distal ischemia syndrome were transient
and did not hamper the subsequent use of AVF. Long-
term complications due to modified hemodynamics of
the limb (i.e. aneurysms and limb hypertrophy) were
rare and never occurred before three years of use; regu-
lar Doppler ultrasound examination and echocardiogra-
phy allowed early detection and proper remedial inter-
ventions. Aneurysms occurred in children with
inhibitors who accessed AVF daily and for a long time,
resulting in high cumulative numbers of AVF punctures.
In these instances, surgical AVF dismantlement must be
planned as soon as ITI is completed or when access to
peripheral veins becomes available, preferably within 3-
4 years from AVF creation. If ITI is still ongoing and AVF
represents the only available venous access, it is advis-
able to remodel the anastomosis prior to dismantle it, in
order to allow ITI completion without interruption. 
In our cohort the need for a venous access was greater
in inhibitor than in non-inhibitor children (75% and
40%, respectively). In patients without inhibitors
CVAD did allow long-term prophylaxis to be main-
tained in a high proportion of cases, while the early
occurrence of infectious complications hampered ITI
completion in the majority of inhibitor patients.10 In a
metanalysis on CVAD use in hemophilic children,2 it
was observed that infectious complications were more
frequent in the presence of inhibitors, while infections
were not observed in our patients using AVF irrespec-
Arteriovenous fistula in children with hemophilia
haematologica | 2009; 94(5) | 691 |
Table 4. Reasons for surgical dismantlement of 9 AVF.
Patients Median duration of AVF
use, years (range)
Transition to peripheral veins 4 6 (4-8.3)
Aneurysmatic dilatation 3 4.5 (3.5-6.6) 
Limb hypertrophy 1 7.2
AVF overflow 1 6.9
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tive of inhibitor status. On this basis, AVF has become
the first-choice venous access in children with
inhibitors. Since AVF maturation was usually achieved
after a median of two months, children candidate to ITI
underwent AVF creation during the time period required
to reach an inhibitor titer below 10 BU/mL, i.e. the value
recommended as the most suitable to start ITI.12 In our
previous experience with ports, ITI had to be interrupt-
ed in 50% of children because of port removal for infec-
tions occurring within the first year of treatment10 while
in this series the adoption of AVF allowed ITI in 95% of
children.
The surgical expertise needed for AVF creation in
hemophilic children represented the main concern for its
widespread use.12 A recent report of a successful experi-
ence with AVFs in a small series of hemophilic children
from the US18 indicated that this limitation can be over-
come by involving expert vascular surgery teams. 
In conclusion, our long-term experience with AVFs in
hemophilic children confirms its feasibility with an
acceptable rate of complications, particularly when
compared with CVAD use. Comprehensive hemophil-
ia treatment centers with surgical expertise and assis-
tance should consider AVF as first-choice access in chil-
dren with inhibitors who usually need a long-lasting
venous access for ITI, since our results highlight the
advantages of AVF use in these patients. Regular fol-
low-up and continuous surveillance on long-term out-
come and complications is ongoing in our series and is
recommended to centers that choose AVF as venous
access in hemophiliacs. 
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